Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Clinical trial NCT04274426 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04274426
- Sponsor
- AGO Research GmbH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-13
- Primary completion
- 2025-12-03
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.